Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/1998
12/03/1998WO1998054197A1 Multicyclic erythromycin derivatives
12/03/1998WO1998054191A1 Salts of optically active sulfoxide derivative
12/03/1998WO1998054190A1 Novel compounds
12/03/1998WO1998054189A1 Spiro-quinuclidine derivatives, their preparation and use
12/03/1998WO1998054188A1 Fused dihydropyrans
12/03/1998WO1998054187A1 Spiro-azacyclic derivatives and their use as therapeutic agents
12/03/1998WO1998054186A1 Salts of aromatic sulphonic acids
12/03/1998WO1998054185A1 2-amino-7-(1-substituted-2-hydroxyethyl)-3,5-dihydro-pyrrolo[3,2-d]pyrimidin-4-ones
12/03/1998WO1998054184A1 1,6-naphthyridine anti-convulsants
12/03/1998WO1998054183A2 Ergoline derivatives and their use as somatostatin receptor antagonists
12/03/1998WO1998054182A1 9-AZABICYCLO(3.3.1)NON-2-ENE AND NONANE DERIVATIVES AS CHOLINERGIC LIGANDS AT NICOTINIC ACh RECEPTORS
12/03/1998WO1998054181A1 8-azabicyclo(3,2,1)oct-2-ene and octane derivatives as cholinergic ligands at nicotinic ach receptors
12/03/1998WO1998054180A1 Novel compounds
12/03/1998WO1998054178A1 Sulfate salt of an hiv protease inhibitor having an improved oral absorption and bioavailability
12/03/1998WO1998054172A1 Novel benzimidazole derivatives as antiulcer agents, process for their preparation and pharmaceutical compositions containing them
12/03/1998WO1998054171A1 Novel form of s-omeprazole
12/03/1998WO1998054170A1 SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)-PHTHALIMIDES AND 1-OXOISOINDOLINES AND METHOD OF REDUCING TNFα LEVELS
12/03/1998WO1998054169A1 Substituted cyclobutylamine derivatives
12/03/1998WO1998054166A1 A new salt
12/03/1998WO1998054161A1 Oxazolidinone antibacterial agents having a thiocarbonyl functionality
12/03/1998WO1998054159A1 Non-steroidal (hetero) cyclically substituted acylanilides with mixed gestagen and androgen activity
12/03/1998WO1998054158A1 QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56lck TYROSINE KINASES
12/03/1998WO1998054157A1 QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p561ck TYROSINE KINASES
12/03/1998WO1998054156A1 QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56lck TYROSINE KINASES
12/03/1998WO1998054153A1 Novel cyclic diamine compounds and medicine containing the same
12/03/1998WO1998054152A1 Azacyclooctane and heptane derivatives, their preparation and usein therapy
12/03/1998WO1998054149A1 Process for obtaining quinapryl hydrochloride and solvates useful for isolating and purifying quinapryl hydrochloride
12/03/1998WO1998054147A1 Cyanoamidines as cell proliferation inhibitors
12/03/1998WO1998054146A1 Cyanoguanidines as cell proliferation inhibitors
12/03/1998WO1998054145A1 Cyanoguanidines as cell proliferation inhibitors
12/03/1998WO1998054144A1 Cyanoguanidines as cell proliferation inhibitors
12/03/1998WO1998054143A1 Cyanoguanidines as cell proliferation inhibitors
12/03/1998WO1998054141A1 Cyanoguanidines as cell proliferation inhibitors
12/03/1998WO1998054138A1 Novel orally active iron (iii) chelators
12/03/1998WO1998054093A1 Novel angiogenesis inhibitors
12/03/1998WO1998053907A1 Betaine product, method for its manufacture, and its use
12/03/1998WO1998053863A2 Composition and methods for transdermal delivery of acid labile drugs
12/03/1998WO1998053853A1 Combined product associating a nucleic acid with a substance breaking up the extracellular matrix for gene therapy
12/03/1998WO1998053839A2 Anti-cancer products for treating cystic fibrosis
12/03/1998WO1998053835A1 The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer
12/03/1998WO1998053834A1 Use of low-molecular-weight heparins for preventing and treating cerebral edemas
12/03/1998WO1998053833A1 Use of low-molecular-weight heparins for preventing and treating central nervous system trauma
12/03/1998WO1998053832A1 Use of hypothalmic inhibitory factor in the treatment of ischemic cardiac malfunction
12/03/1998WO1998053829A1 Use of oligosaccharide for preventing blood clotting in extracorporeal blood circuits
12/03/1998WO1998053828A1 Israpafant-containing water-base preparations
12/03/1998WO1998053826A1 Non-steroidal agonist compounds and their use in male hormone therapy
12/03/1998WO1998053825A1 Analgesic drug composition containing a capsaicinoid and potentiator therefor
12/03/1998WO1998053824A1 Novel process
12/03/1998WO1998053823A1 5-HT1A AND 5-HT1Dα ANTAGONISTS
12/03/1998WO1998053822A1 Pyridine-thiols reverse mucocutaneous aging
12/03/1998WO1998053821A1 USE OF 4-SUBSTITUTED TETRAHYDROPYRIDINES FOR MAKING MEDICINES ACTING ON TGF-β1
12/03/1998WO1998053820A1 Treatment of schizophrenia and psychosis
12/03/1998WO1998053819A1 Therapeutic agent for erection failure
12/03/1998WO1998053818A1 Sulfonamides as cell adhesion inhibitors
12/03/1998WO1998053817A1 Biarylalkanoic acids as cell adhesion inhibitors
12/03/1998WO1998053816A1 Method of treating isolated systolic hypertension
12/03/1998WO1998053815A1 Transdermal drug delivery device for the delivery of tropisetron or granisetron
12/03/1998WO1998053814A1 Heterocyclic amide compounds as cell adhesion inhibitors
12/03/1998WO1998053812A1 Inhibitors of naaladase enzyme activity
12/03/1998WO1998053811A1 Method and compositions for administering taxanes orally to human patients
12/03/1998WO1998053810A1 Pharmaceutical injection solution containing taxol
12/03/1998WO1998053809A1 Ophthalmic compositions for treating ocular hypertension
12/03/1998WO1998053808A1 Process for preparing a reactive pharmaceutical product for the detection of gastrointestinal disorder caused by bacteria in the gastrointestinal superior tract
12/03/1998WO1998053806A1 Medicinal compositions for topical administration containing vitamin d and vitamin k
12/03/1998WO1998053805A1 Clear, injectable formulation of an anesthetic compound
12/03/1998WO1998053803A1 Pharmaceutical formulation of omeprazole
12/03/1998WO1998053802A1 Multi-layered osmotic device
12/03/1998WO1998053801A1 Conjugated peptide nucleic acids having enhanced cellular uptake
12/03/1998WO1998053798A1 Solid pharmaceutical preparation
12/03/1998WO1998053795A1 Cosmetic and dermopharmaceutical compositions containing threonine or serine derivatives
12/03/1998WO1998053711A1 Dehydration plant
12/03/1998WO1998053709A1 Aminoacid formulations for third age persons and process for calculating such formulations
12/03/1998WO1998045712A3 20 human secreted proteins
12/03/1998WO1998041631A3 β-CATENIN, TCF-4, AND APC INTERACT TO PREVENT CANCER
12/03/1998WO1998041238A3 Methods and kits for treating and diagnosing leiomyomas
12/03/1998WO1998040375A3 COMBINATION OF ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS
12/03/1998WO1998038994A3 Combined preparation of 2-methylthiazolidine-2,4-dicarboxylic acid and paracetamol
12/03/1998WO1998037873A3 Method for reducing secretion of apolipoprotein b in animals by administering conjugated linoleic acid
12/03/1998DE19724187A1 11beta-Arylsubstituierte 14,17-Ethanoestratriene, Verfahren zur Herstellung dieser Verbindungen, sowie ihre Verwendung zur Herstellung von Arzneimitteln 11beta-aryl-substituted 14,17-ethanoestratrienes, processes for preparing these compounds, and their use for the preparation of medicaments
12/03/1998DE19721470A1 Die Verwendung von N-Acetyl-L-Cystein zur Behandlung von männlicher Unfruchtbarkeit The use of N-acetyl-L-cysteine ​​for the treatment of male infertility
12/03/1998DE19719652A1 Use of tissue factor
12/03/1998CA2528646A1 Solid pharmaceutical preparation
12/03/1998CA2292877A1 Cyanoguanidines as cell proliferation inhibitors
12/03/1998CA2292876A1 Cyanoguanidines as cell proliferation inhibitors
12/03/1998CA2292580A1 Substituted cyclobutylamine derivative
12/03/1998CA2291881A1 Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
12/03/1998CA2291839A1 Conjugated peptide nucleic acids having enhanced cellular uptake
12/03/1998CA2291778A1 Heterocyclic amide compounds as cell adhesion inhibitors
12/03/1998CA2291777A1 Ophthalmic compositions for treating ocular hypertension
12/03/1998CA2291774A1 Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
12/03/1998CA2291762A1 Biarylalkanoic acids as cell adhesion inhibitors
12/03/1998CA2291750A1 Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
12/03/1998CA2291735A1 Israpafant-containing water-base preparations
12/03/1998CA2291728A1 Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
12/03/1998CA2291709A1 Novel angiogenesis inhibitors
12/03/1998CA2291708A1 Sulfonamides as cell adhesion inhibitors
12/03/1998CA2291698A1 Osf2/cbfa1 compositions and methods of use
12/03/1998CA2291674A1 5-ht1a and 5-ht1d.alpha. antagonists
12/03/1998CA2291595A1 Dna methyltransferase genomic sequences and antisense oligonucleotides
12/03/1998CA2291590A1 Combined product associating a nucleic acid with a substance breaking up the extracellular matrix for gene therapy
1 ... 6571 6572 6573 6574 6575 6576 6577 6578 6579 6580 6581 6582 6583 6584 6585 6586 6587 6588 6589 6590 6591 ... 7860